Factors affecting the efficacy and safety of docetaxel combined with platinum in the treatment of advanced non-small cell lung cancer

Wang, FengLi; Zhao, Chen-Yang; Xiao, Wen; Zheng, Qingshan; Li, Lujin

doi:10.1080/17512433.2021.1976638

Cited by 3 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NSCLC is the most prevalent subtype, accounting for 85% of all lung cancer occurrences [1]. While conventional chemotherapy, such as docetaxel, was authorized as a second-line therapy for progressive NSCLC, based on improved survival compared to optimal supportive care, its effectiveness is offset by significant adverse events [2]. With the advancement of immune checkpoint inhibitors (ICIs), they have become a more viable option for individuals with NSCLC [3].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials

Chen

Cheng

et al. 2022

Disease Markers

View full text Add to dashboard Cite

Importance. Following the research, we discovered that other meta-analyses contained incomplete genes or did not include a sufficient number of trials. To address these limitations, this meta-analysis sought to find studies examining the extent toward epidermal growth factor receptor (EGFR) or KRAS or mutation status gives data on both the probability of a specific illness outcome very independent of treatment (prognostic factor) and possibility of advantage from a particular therapy (predictive factor) in non-small-cell lung cancer (NSCLC) patients. Objective. To assess and compare the effectiveness of immune checkpoint inhibitors vs. chemotherapy for KRAS-mutant or EGFR-mutant non-small-cell lung cancers. Methods. Until February 19, 2022, Cochrane Library, PubMed, Web of Science, and Embase were searched for relevant randomized controlled trials (RCTs) in NSCLC. Progression-free survival (PFS) and overall survival (OS) were used as outcome measures. The studies were conducted using the Cochrane methodology for meta-analyses, and all statistical analyses were made with Review Manager Software (RevMan version 5.4). Results. Our meta-analysis included nine clinical trials including 5633 participants with NSCLC. Immune checkpoint drugs extended OS (hazard ratio (HR), 0.67; 95% confidence interval (CI), 0.60–0.76) and PFS (HR, 0.44; 95% CI, 0.35-0.56) in patients with EGFR wild-type compared to chemotherapy alone, whereas programmed cell death 1 ligand 1 (PD-L1)/programmed cell death-1 (PD-1) inhibitors with chemotherapy versus chemotherapy extended PFS in NSCLC patients with EGFR mutations (HR, 0.63; 95% CI, 0.42-0.94). Meanwhile, immune checkpoint inhibitors vs. chemotherapy improved the OS (HR, 0.65; 95% CI, 0.48–0.88) and PFS (HR, 0.49; 95% CI, 0.36–0.66) of NSCLC patients with KRAS mutation. NSCLCs with KRAS G12C mutation had a much better PFS with ICIs than with chemotherapy (HR, 0.38; 95% CI, 0.21–0.71). Conclusion. This research revealed that individuals with EGFR wild-type NSCLC or KRAS mutation may benefit from PD-L1/PD-1 inhibitors and that PD-L1/PD-1 inhibitors in combination with chemotherapy seem to be more successful than chemotherapy alone in NSCLC patients with EGFR mutation.

show abstract

Section: Introductionmentioning

confidence: 99%

“…2 = 0.82, df = 1 (P = 0.37); 1 2 = 0% Test for overall effect: Z = 3.06 (P = 0log [Hazard ratio] SE Weight Hazard ratio IV, Fixed, 95% Cl Hazard ratio IV, Fixed, 95% Cl…”

mentioning

confidence: 99%

The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials

Chen

Cheng

et al. 2022

Disease Markers

View full text Add to dashboard Cite

show abstract

“…A study conducted by Wang et al revealed that the frequency of administration of Docetaxel was related to the occurrence of neutropenia as the incidence rate of neutropenia after once-per-cycle was significantly higher than that observed after twiceper cycle. [19] As well, the duration of one cycle also plays a role since the incidence was significantly higher in 21-day cycles than in 28-day cycles [19]. Other than myelosuppression, it can lead to neuropathy, diarrhea, stomatitis, nausea and vomiting.…”

Section: Discussionmentioning

confidence: 99%

Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)

et al. 2023

View full text Add to dashboard Cite

Background: Lung cancer is the number one cause of mortality among all types of cancer worldwide. Its treatment landscape has shifted from the classic chemotherapy alone to newer regimens based on the discovery of new immunotherapy and targeted therapy drugs. However, chemotherapy is still an option for treatment of advanced non-small cell lung cancer (NSCLC) after progression on immunotherapy alone or in combination with first-line chemotherapy. Methods: This is a retrospective study based on chart review of patients diagnosed with advanced NSCLC cases who received Docetaxel as second or third line after being treated by immunotherapy and/or chemotherapy in previous lines. The data was collected from the medical records of physicians' clinics in three different hospital centers in Lebanon over the period of 5 years from July 2015 until December 2020. February 2021 was data analysis cut off time. The main aim was to assess the role of Docetaxel post-chemoimmunotherapy for patients with diagnosed NSCLC.Results: A total of 21 patients were included in this study. The majority of our patients were males (81%). As for histologic type, most patients had non-squamous lung cancer (67%) as compared to 33% who had squamous lung cancer. Overall, our study reported a 24% response rate to Docetaxel including stable disease and partial response and a median progression free survival (PFS) of 3 months. The mean time interval elapsed from diagnosis to the initiation of Docetaxel was 11.5 months.Conclusion: New therapeutic options should be validated for the treatment of NSCLC in the second and subsequent lines of therapy considering the poor prognosis of this disease. The chemotherapy in second and third line may keep an important role in the treatment after progression on newer agents, but it needs more evidence in prospective studies including a larger number of patients.

show abstract

Quantitative evaluation of therapy options for relapsed/refractory diffuse large B-cell lymphoma: A model-based meta-analysis

Hou

et al. 2023

Pharmacological Research

View full text Add to dashboard Cite

Factors affecting the efficacy and safety of docetaxel combined with platinum in the treatment of advanced non-small cell lung cancer

Cited by 3 publications

References 23 publications

The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials

The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials

Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)

Quantitative evaluation of therapy options for relapsed/refractory diffuse large B-cell lymphoma: A model-based meta-analysis

Contact Info

Product

Resources

About